Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | active not recruiting | Phase 1 / Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 |
| NCT03580928 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL(AVO) | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 72 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL(CRETI-NH) | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03513562 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | active not recruiting | Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)(BRUIN CLL-322) | active not recruiting | Phase 3 | 600 | Loxo Oncology, Inc.INDUSTRY | 23 | Jan 29, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | active not recruiting | Phase 2 | 150 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04928599 | Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States | active not recruiting | — | 100 | Children's Oncology GroupNETWORK | 2 | Jan 8, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07269587 | A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 | active not recruiting | — | 275 | Ruijin HospitalOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04167683 | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant | active not recruiting | — | 144 | Rigshospitalet, DenmarkOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04963946 | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia(STAIR) | active not recruiting | Phase 2 | 160 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05645172 | Retention Rate of Acalabrutinib in a Non-interventional Setting(RETAIN) | active not recruiting | — | 137 | AstraZenecaINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07238907 | A Multi-center Retrospective Study of INO Treating B-ALL | active not recruiting | — | 102 | Ruijin HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03233854 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 56 | Stanford UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)(CARPASCIO) | active not recruiting | Phase 1 | 7 | Baylor College of MedicineOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04684563 | huCART19-IL18 in CD19+ Cancers | active not recruiting | Phase 1 | 72 | University of PennsylvaniaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | active not recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05236764 | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion(HAPLOTAB) | active not recruiting | N/A | 3 | Baylor College of MedicineOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03620058 | CART22 Alone or in Combination With huCART19 for ALL | active not recruiting | Phase 1 | 23 | University of PennsylvaniaOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05878184 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | active not recruiting | Phase 1 | 16 | Sana BiotechnologyINDUSTRY | 2 | Oct 2, 2025 | clinicaltrials |
| NCT05971251 | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | University of Alabama at BirminghamOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | active not recruiting | Phase 2 | 24 | Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04606433 | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 47 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05993949 | Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 8 | Stanford UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05192889 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | active not recruiting | Phase 1 / Phase 2 | 35 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT02716233 | A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents(CAALL-F01) | active not recruiting | Phase 3 | 2,044 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04501939 | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax(Venetoclax) | active not recruiting | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04541056 | Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae | active not recruiting | N/A | 60 | Norwegian University of Science and TechnologyOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 12 | Acerta Pharma BVINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04159779 | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece | active not recruiting | — | 180 | AbbVieINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04851717 | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | active not recruiting | Phase 2 / Phase 3 | 100 | Acacia Pharma LtdINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT05936853 | The EPigenetic Consequences in Children of Intravenous vs Volatile Anaesthesia for Surgery (EPIVA)(EPIVA) | active not recruiting | N/A | 16 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Jun 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 25, 2026source: clinicaltrials